The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
Open accessAbstract
BACKGROUND: Most HIV-1-infected patients on effective antiretroviral therapy (ART) with plasma HIV-1 RNA levels below the detection limits of commercial assays have residual viremia measurable by more sensitive methods. We assessed whether adding raltegravir lowered the level of residual viremia in such patients. METHODS AND FINDINGS: Patients receiving ART who had plasma HIV-1 RNA levels below 50 copies/mL but detectable viremia by single copy assay (SCA) were randomized to add either raltegravir or placebo to their ART regimen for 12 weeks; patients then crossed-over to the other therapy for an additional 12 weeks while continuing pre-study ART. The primary endpoint was the plasma HIV-1 RNA by SCA averaged between weeks 10 and 12 (10/12) compared between treatment groups. Fifty-three patients were enrolled. The median screening HIV-1 RNA was 1.7 copies/mL. The HIV-1 RNA level at weeks 10/12 did not differ significantly between the raltegravir-intensified (n = 25) and the placebo (n = 24) groups (median 1.2 versus 1.7 copies/mL, p = 0.55, Wilcoxon rank sum test), nor did the change in HIV-1 RNA level from baseline to week 10/12 (median -0.2 and -0.1 copies/mL, p = 0.71, Wilcoxon rank sum test). There was also no significant change in HIV-1 RNA level from weeks 10/12 to weeks 22/24 after patients crossed-over. There was a greater CD4 cell count increase from baseline to week 12 in the raltegravir-intensified group compared with the placebo group (+42 versus -44 cells/mm(3), p = 0.082, Wilcoxon rank sum test), which reversed after the cross-over. This CD4 cell count change was not associated with an effect of raltegravir intensification on markers of CD4 or CD8 cell activation in blood. CONCLUSION: In this randomized, double-blind cross-over study, 12 weeks of raltegravir intensification did not demonstrably reduce low-level plasma viremia in patients on currently recommended ART. This finding suggests that residual viremia does not arise from ongoing cycles of HIV-1 replication and infection of new cells. New therapeutic strategies to eliminate reservoirs that produce residual viremia will be required to eradicate HIV-1 infection. TRIAL REGISTRATION: ClinicalTrials.gov NCT00515827
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hunt, P. W., Martin, J. N., Sinclair, E., Bredt, B., Hagos, E., Lampiris, H., & Deeks, S. G. (2003) · The Journal of Infectious Diseases · doi:10.1086/374786 · Cited by 852
The Challenge of Finding a Cure for HIV Infection
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., & Pomerantz, R. J. (2009) · Science · doi:10.1126/science.1165706 · Cited by 846
Self-citationRaltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
Self-citationLow-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G. J., Brun, S. C., Kempf, D. J., Mellors, J. W., Coffin, J. M., & King, M. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800050105 · Cited by 638
Self-citationLennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V. R., Berger, D. S., Zhao, J., Xu, X., Williams-Diaz, A., Rodgers, A. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60918-1 · Cited by 625
Palmer, S., Wiegand, A. P., Maldarelli, F., Bazmi, H., Mican, J. M., Polis, M., Dewar, R. L., Planta, A., Liu, S., Metcalf, J. A., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4531-4536.2003 · Cited by 604
Self-citationJ Buzón, M., Massanella, M., Llibre, J. M., Esteve, A., Dahl, V., Puertas, M. C., Gatell, J. M., Domingo, P., Paredes, R., Sharkey, M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2111 · Cited by 551
Self-citationDornadula, G. (1999) · JAMA · doi:10.1001/jama.282.17.1627 · Cited by 463
Dinoso, J. B., Kim, S. Y., Wiegand, A. M., Palmer, S. E., Gange, S. J., Cranmer, L., O'Shea, A., Callender, M., Spivak, A., Brennan, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903107106 · Cited by 441
Self-citationHsue, P. Y., Hunt, P. W., Schnell, A., Kalapus, S. C., Hoh, R., Ganz, P., Martin, J. N., & Deeks, S. G. (2009) · AIDS · doi:10.1097/qad.0b013e32832b514b · Cited by 388
Cited by
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Self-citationComparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
Eriksson, S., Graf, E. H., Dahl, V., Strain, M. C., Yukl, S. A., Lysenko, E. S., Bosch, R. J., Lai, J., Chioma, S., Emad, F., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003174 · Cited by 567
Self-citationTowards an HIV cure: a global scientific strategy
The International AIDS Society Scientific Working Group on HIV Cure (2012) · Nature Reviews Immunology · doi:10.1038/nri3262 · Cited by 554
Siliciano, R. F., & Greene, W. C. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007096 · Cited by 513
Redefining the Viral Reservoirs that Prevent HIV-1 Eradication
Eisele, E., & Siliciano, R. F. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.010 · Cited by 474
“Numerous studies with several different intensification drugs have all shown that intensification has no effect on residual viremia (Dinoso et al., 2009; Gandhi et al., 2010; Yukl et al., 2010b).”
BackgroundImmune activation and HIV persistence: implications for curative approaches to HIV infection
Klatt, N. R., Chomont, N., Douek, D. C., & Deeks, S. G. (2013) · Immunological Reviews · doi:10.1111/imr.12065 · Cited by 435
HIV and Inflammation: Mechanisms and Consequences
Hunt, P. W. (2012) · Current HIV/AIDS Reports · doi:10.1007/s11904-012-0118-8 · Cited by 417
Henrich, T. J., Hanhauser, E., Marty, F. M., Sirignano, M. N., Keating, S., Lee, T.-H., Robles, Y. P., Davis, B. T., Li, J. Z., Heisey, A., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m14-1027 · Cited by 401
Halper-Stromberg, A., Lu, C.-L., Klein, F., Horwitz, J. A., Bournazos, S., Nogueira, L., Eisenreich, T. R., Liu, C., Gazumyan, A., Schaefer, U., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.043 · Cited by 381
Residual Immune Dysregulation Syndrome in Treated HIV infection
Lederman, M. M., Funderburg, N. T., Sekaly, R. P., Klatt, N. R., & Hunt, P. W. (2013) · Advances in Immunology · doi:10.1016/b978-0-12-407707-2.00002-3 · Cited by 348
Self-citationTargeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
HIV-1 transcription and latency: an update
Van Lint, C., Bouchat, S., & Marcello, A. (2013) · Retrovirology · doi:10.1186/1742-4690-10-67 · Cited by 338
An Integrated Overview of HIV-1 Latency
Ruelas, D. S., & Greene, W. C. (2013) · Cell · doi:10.1016/j.cell.2013.09.044 · Cited by 324
Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing
Kaminski, R., Chen, Y., Fischer, T., Tedaldi, E., Napoli, A., Zhang, Y., Karn, J., Hu, W., & Khalili, K. (2016) · Scientific Reports · doi:10.1038/srep22555 · Cited by 315
Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults
Hsue, P. Y., Deeks, S. G., & Hunt, P. W. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis200 · Cited by 269
Gandhi, R. T., Landovitz, R. J., Sax, P. E., Smith, D. M., Springer, S. A., Günthard, H. F., Thompson, M. A., Bedimo, R. J., Benson, C. A., Buchbinder, S. P., et al. (2025) · JAMA · doi:10.1001/jama.2024.24543 · Cited by 265
Self-citationPredicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
Hill, A. L., Rosenbloom, D. I. S., Fu, F., Nowak, M. A., & Siliciano, R. F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406663111 · Cited by 265
HIV reservoirs: pathogenesis and obstacles to viral eradication and cure
Chun, T.-W., & Fauci, A. S. (2012) · AIDS · doi:10.1097/qad.0b013e328353f3f1 · Cited by 175
Wiegand, A., Spindler, J., Hong, F. F., Shao, W., Cyktor, J. C., Cillo, A. R., Halvas, E. K., Coffin, J. M., Mellors, J. W., & Kearney, M. F. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617961114 · Cited by 165
Self-citation
Metadata
- Authors
- Gandhi, R. T., Zheng, L., Bosch, R. J., Chan, E. S., Margolis, D. M., Read, S., Kallungal, B., Palmer, S., Medvik, K., Lederman, M. M., Alatrakchi, N., Jacobson, J. M., Wiegand, A., Kearney, M., Coffin, J. M., Mellors, J. W., Eron, J. J., & on behalf of the AIDS Clinical Trials Group A5244 team
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-08-10
- Volume
- 7
- Issue
- 8
- Pages
- e1000321
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2113669930
- Cited by
- 304
- References
- 22
- FWCI
- 21.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.